



## News Release

### **Cancellation of the Purchase Schedule of Nuvaxovid® Intramuscular Injection by the Japanese Government**

**OSAKA, Japan and CAMBRIDGE, Massachusetts, February 10, 2023**— Takeda (**TSE:4502/NYSE:TAK**) today announced that it received a notification from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) cancelling the purchase of additional doses of the COVID-19 vaccine Nuvaxovid® Intramuscular Injection. In 2021, the MHLW agreed to purchase 150 million doses of the vaccine from Takeda. As a result of this notification, the government's purchase of the remaining 141.76 million doses, which excludes those already supplied by Takeda, will be cancelled. The agreement had been announced on September 7, 2021: “Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan”.

Since Nuvaxovid is manufactured in response to the orders placed by the MHLW, there will be no disposal of manufactured products in association with the cancellation of this purchase schedule. Available doses of Nuvaxovid already supplied to the market can still be used as an option for individuals who cannot receive a bivalent omicron mRNA vaccine, or who wish to receive a recombinant protein vaccine.

Takeda is working with Novavax to develop vaccines against the future variants. In an effort to contribute to public health in Japan, Takeda will continue to work closely with the MHLW on the delivery of COVID-19 vaccines in FY 2023, including the potential delivery of vaccines for the Omicron variant.

There is no change in Takeda’s full year consolidated forecasts for the fiscal year ending March 31, 2023 (FY2022), as the financial impacts from the cancellation of the purchase schedule is immaterial. While Takeda recognizes a part of contractual amount as revenue under the terms of the agreement, there is no change in the approximately 50.0 billion JPY revenue contribution from COVID-19 vaccines, including Spikevax Intramuscular Injection, in FY2022.

#### **About Takeda**

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit <https://www.takeda.com>.

**Media Contacts:****Japanese Media**

Tatsuhiko Kanoo

[tatsuhiko.kanoo@takeda.com](mailto:tatsuhiko.kanoo@takeda.com)**U.S. and International Media**

Rachel Higgins

[rachel.higgins@takeda.com](mailto:rachel.higgins@takeda.com)

+1 917-796-8703

**Important Notice**

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

**Forward-Looking Statements**

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission,

available on Takeda's website at: <https://www.takeda.com/investors/sec-filings/> or at [www.sec.gov](http://www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

**Medical information**

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

###